Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 72 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NF[yc5hEgXSxdH;4bYMhSXO|YYm= NWKwfJBpPDhiaB?= MV\EUXNQ M4XNfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2= M2\pV|IyPTd{NUi5
BAF3 NFvHR5hEgXSxdH;4bYMhSXO|YYm= NVfCRnc3PDhiaB?= M1\keWROW09? MoDhR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh|ryP Mn\mNlE2PzJ3OEm=
BAF3 MmDVR5l1d3SxeHnjJGF{e2G7 MoXXOFghcA>? MUnEUXNQ MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR|UxKG:oIECuNlgh|ryP MkXiNlE2PzJ3OEm=
Kelly MXPDfZRwfG:6aXOgRZN{[Xl? NH3CNIZFVVOR M{HIS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN M1PRWVIyPTd{NUi5
SH-SY5Y NGjmTGlEgXSxdH;4bYMhSXO|YYm= M1\QZmROW09? M1ThW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC53MzFOwG0> MmHHNlE2PzJ3OEm=
SMS-KCN NFO1[ZNEgXSxdH;4bYMhSXO|YYm= NELCeo9FVVOR M3jiSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> MYeyNVU4OjV6OR?=
BAF3 NWnFUoh5S3m2b4TvfIlkKEG|c3H5 MoXCOFghcA>? MWfEUXNQ MkLwR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP MnnSNlE2PzJ3OEm=
3T3 NHHST49HfW6ldHnvckBCe3OjeR?= NGDyV5QyKGh? M4PZOmROW09? NXzPd3JFUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP NWfpU3JrOjF6MUK0NVQ>
3T3-E NVO3OpFGTnWwY4Tpc44hSXO|YYm= MW[xJIg> MY\EUXNQ MWDJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=> MYGyNVgyOjRzNB?=
A549 M{POWWtqdmG|ZTDBd5NigQ>? NFnSe2syKGh? NF\sS5JFVVOR MlnKTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN NF\wengzOThzMkSxOC=>
BAF3-BCL NHXMR21HfW6ldHnvckBCe3OjeR?= MVKxJIg> MmTySG1UVw>? NF2zWnZKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP MorDNlE5OTJ2MUS=
HEK293 MXTGeY5kfGmxbjDBd5NigQ>? M{S5[FEhcA>? M1HMeGROW09? MkXJTY5pcWKrdHnvckBw\iCDWFygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>? NVGyXXpwOjF6MUK0NVQ>
HEK293 MXPGeY5kfGmxbjDBd5NigQ>? MU[xJIg> MUXEUXNQ M3T5eWlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? NUfReZBjOjF6MUK0NVQ>
Jurkat MmLDSpVv[3Srb36gRZN{[Xl? NFjPOHUyKGh? MmXtSG1UVw>? NFroZZVKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh|ryP Mkj1NlE5OTJ2MUS=
KARPAS299 M1HQb2tqdmG|ZTDBd5NigQ>? Mlj3NUBp Ml;TSG1UVw>? NVG0fGZOUW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NID4SGQzOThzMkSxOC=>
PAE M2PxR2Z2dmO2aX;uJGF{e2G7 M1;LSFEhcA>? Mn\PSG1UVw>? MoXRTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? NGfRTIszOThzMkSxOC=>
BAF3 MWrGeY5kfGmxbjDBd5NigQ>? MVeyMVMh\A>? Ml3HSG1UVw>? NHf4UHlKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NY[zdZh2OjN5NEKyOVI>
KARPAS299 MoTOR5l1d3SxeHnjJGF{e2G7 MnfNNk0{KGR? MV7EUXNQ M3zV[mlEPTB;MD6wOlQzKM7:TR?= MlW2NlM4PDJ{NUK=
EBC1 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp NEjPPG5FVVOR NV\SSIhGUUN3ME2wMlAzOyEQvF2= MUCyN|k6OzN{OB?=
HCT116 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ezZlczKGh? NGnKPFRFVVOR MW\JR|UxRTF2LkiyJO69VQ>? MUeyN|k6OzN{OB?=
MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfUO|IhcA>? MnfKSG1UVw>? M2f0d2lEPTB;OT61PEDPxE1? NH\ybGEzOzl7M{OyPC=>
MDA-MB-231 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp Mme3SG1UVw>? M3q1[WlEPTB;MUCuPEDPxE1? Mn7NNlM6QTN|Mki=
MKN45 M4nRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFO|IhcA>? NYXSU|V4TE2VTx?= MlW0TWM2OD1yLkCxN{DPxE1? NXHFTlROOjN7OUOzNlg>
NCI-H441 NEmzVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPFZWk4OiCq NEXKSpdFVVOR MVvJR|UxRTF5LkK1JO69VQ>? MUmyN|k6OzN{OB?=
NCI-H661 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO0O|IhcA>? MlGwSG1UVw>? Mmn0TWM2OD1zMT60O{DPxE1? M4XiOFI{QTl|M{K4
SK-MEL-28 M374ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rMVVczKGh? MlTWSG1UVw>? MUnJR|UxRTFyLkm3JO69VQ>? Ml:2NlM6QTN|Mki=
SKOV3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S4UlczKGh? MVXEUXNQ MlfyTWM2OD1zMj64OUDPxE1? M4[0d|I{QTl|M{K4
SNU5 M3;DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPD[Wg4OiCq NV[xNppoTE2VTx?= NH\ofWRKSzVyPUCuNFE3KM7:TR?= MYWyN|k6OzN{OB?=
NCI-H2228 M1zl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5c|czKGh? MXzEUXNQ M3jvSGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFzODFOwG0> MoftNlQ1OzJ7MEm=
NCI-H3122 M{PIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp NXPs[pVnTE2VTx?= NX;idXdJUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>? NW\TOFlPOjR2M{K5NFk>
NCI-H3122 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnwXWlsPzJiaB?= MkjrSG1UVw>? NXHDT3dUUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO MmLLNlQ1OzJ7MEm=
NCI-H3122 NVjFXXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLNS3o4OiCq MYrEUXNQ MXTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= NFPwN5kzPDR|MkmwPS=>
NIH-3T3 MkLsT4lv[XOnIFHzd4F6 Mlv2NUBp MXfEUXNQ MlrKTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MlPWNlQ1OzJ7MEm=
NIH-3T3 NYjBR3UxU2mwYYPlJGF{e2G7 MU[xJIg> MlzISG1UVw>? NUiwWWpEUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP M3;MXVI1PDN{OUC5
NIH-3T3 M{TzUWtqdmG|ZTDBd5NigQ>? MlHDNUBp MoS3SG1UVw>? NX7SWpBwUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP MWiyOFQ{OjlyOR?=
NIH-3T3 MonQT4lv[XOnIFHzd4F6 MWGxJIg> NXvwdoZrTE2VTx?= Mn7wTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC56NEOg{txO NGrzSGszPDR|MkmwPS=>
NIH-3T3 M{XEOWtqdmG|ZTDBd5NigQ>? MmrLNUBp NETqZYFFVVOR MmnDTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO M1vnTVI1PDN{OUC5
BAF3 Mln4SpVv[3Srb36gRZN{[Xl? MlL5O|IhcA>? NV;XSXQxTE2VTx?= NFHxUo1KdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO NHizUXEzPDR4OE[zNi=>
BAF3 M4\YSWN6fG:2b4jpZ{BCe3OjeR?= NVnKRnpOPzJiaB?= MVrEUXNQ NX;5ZYRZUUN3ME2wMlk5KM7:TR?= M3\hNVI1PDZ6NkOy
NIH-3T3 NGrneVhMcW6jc3WgRZN{[Xl? NXfZdmRtOSCq MmDmTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO NFf0c2QzPDhzOUGxOi=>
NIH-3T3 NHTNeW9McW6jc3WgRZN{[Xl? MYOxJIg> NFXIbYFKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkS3PEDPxE1? MX6yOFgyQTFzNh?=
NIH-3T3 M3T2fWtqdmG|ZTDBd5NigQ>? MoruNUBp MYjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> MorWNlQ5OTlzMU[=
NIH-3T3 NHnrXVlMcW6jc3WgRZN{[Xl? Mm\hNUBp NHnFO5hKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= M4TJ[VI1QDF7MUG2
KARPAS299 NGL0flJMcW6jc3WgRZN{[Xl? MnrlPVAhdWmw MX;EUXNQ MYHJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> MVeyOFkxODd3MB?=
MKN 45 MojUT4lv[XOnIFHzd4F6 NWT2Wm94OSCq MmHNSG1UVw>? Mkf3TY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO MUmyOFkxODd3MB?=
A549 NX70NopwS3m2b4TvfIlkKEG|c3H5 MVu0PEBp MWXEUXNQ NFrvRmRKSzVyIH;mJFQvODh2IN88US=> M{PIN|I1QTByOEOw
NCI-H1975 MWrDfZRwfG:6aXOgRZN{[Xl? MVu0PEBp NFfiO4lFVVOR NY\ub4k6UUN3MDDv[kA4NjV3MTFOwG0> NIXUTIszPDlyMEizNC=>
NCI-H1993 NGPSU|JEgXSxdH;4bYMhSXO|YYm= MUi0PEBp MV;EUXNQ NInETY5KSzVyIH;mJFAvODZzIN88US=> M{\0Z|I1QTByOEOw
NCI-H1993 NH\oRXlCeG:2b4Ppd{BCe3OjeR?= MnvsNUDPxE1? MWWyOEBp NGn5fW9FVVOR M4nQNIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= M2jOU|I1QTByOEOw
NIH-3T3 MlTpR5l1d3SxeHnjJGF{e2G7 M{fo[|Q5KGh? NFezTpdFVVOR M3TYbmlEPTBib3[gNE4{PjRizszN NHTpXIMzPDlyMEizNC=>
EBC1 NXO5S4NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC3NkBp M1fXdGROW09? NX;SdIExUUN3MDDv[kAxNjByNkmg{txO NUPNb3JZOjR7MEC4N|E>
KARPAS299 M{i5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NkBp NXG3PFV6TE2VTx?= NXPoUXVJUUN3MDDv[kAxNjJizszN NGC1T2wzPDlyMEizNS=>
NB1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTlzLkm4JI5O M13ER3NCVkeHUh?=
NCI-SNU-5 NE[4RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDzNIY{UUN3ME2xNFUvPzVibl2= M3zDfHNCVkeHUh?=
SR NGnUN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF{Nj6zNUBvVQ>? M3XWZ3NCVkeHUh?=
SF539 M3L4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLkTWM2OD1{MESuNlQhdk1? MVHTRW5ITVJ?
SU-DHL-1 NUHMZ3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD1|M{[uPFIhdk1? NWnzUVVMW0GQR1XS
SCC-3 NVLLVlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSzO|JKSzVyPUO1Ok44PiCwTR?= MlnIV2FPT0WU
DEL M2CzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36zPGlEPTB;M{[5Mlkhdk1? MVLTRW5ITVJ?
CTV-1 NIP3dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXhV2dnUUN3ME21PVYvPDhibl2= M2jVU3NCVkeHUh?=
EM-2 NFnuT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG3TWM2OD14MEGuN|Qhdk1? MlTKV2FPT0WU
MHH-CALL-2 M3vQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxUIFvUUN3ME22PFIvPTdibl2= M1fvUnNCVkeHUh?=
KM12 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTmV4FPUUN3ME23NFYvQSCwTR?= MoDjV2FPT0WU
KINGS-1 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7DTWM2OD15NEmuO|Uhdk1? NYrpdGhmW0GQR1XS
MEG-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorlTWM2OD16NUeuOlYhdk1? M4X2UHNCVkeHUh?=
BV-173 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnieldKSzVyPUGuNFU6QTdizszN M2LFU3NCVkeHUh?=
LAMA-84 M3PxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\PU4tUUUN3ME2xMlM5Ojh{IN88US=> NWPLPYNVW0GQR1XS
KARPAS-299 NEXI[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rONmlEPTB;MT60NFg3OSEQvF2= MUXTRW5ITVJ?
K-562 M{TlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzPTGFKSzVyPUGuO|IzPjlizszN NHvEW|FUSU6JRWK=
SK-LMS-1 M4DxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT1fWhKSzVyPUGuO|Y5PjdizszN MoO1V2FPT0WU
MOLT-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLtNGFKSzVyPUGuPVU2PzVizszN M3PkR3NCVkeHUh?=
CMK NUTqUolrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwOU[xOVkh|ryP M2jh[HNCVkeHUh?=
ST486 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNEOwO|Mh|ryP NF7nTIxUSU6JRWK=
CI-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13GcGlEPTB;Mj60PVY2QSEQvF2= NYC2XZBnW0GQR1XS
KP-N-RT-BM-1 NULQeZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVroOJp[UUN3ME2yMlcxOTJ{IN88US=> NXL4eWI2W0GQR1XS
ALL-PO NFrWZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTvdWR{UUN3ME2zMlE5OjB5IN88US=> MnP1V2FPT0WU
KS-1 M1zYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvhephnUUN3ME2zMlIyOjJ3IN88US=> NHKxOmtUSU6JRWK=
Becker NYH0VnpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nzUWlEPTB;ND6yN|k{KM7:TR?= MVzTRW5ITVJ?
GDM-1 NHL3dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\Dd5dYUUN3ME20MlI1PjF5IN88US=> MW\TRW5ITVJ?
BC-1 M2HNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fFdmlEPTB;ND60PVI4PyEQvF2= M3;aVnNCVkeHUh?=
NB14 NI\QO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn0fWN4UUN3ME20Mlg{PTJ2IN88US=> MX\TRW5ITVJ?
NOS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[wfZdKSzVyPUWuN|M5PzRizszN M2HoOnNCVkeHUh?=
MZ1-PC NELaR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TFPGlEPTB;NT64NlE2OSEQvF2= NIjifIpUSU6JRWK=
A498 M{DTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZwMEi0O|Mh|ryP MlLXV2FPT0WU
EW-16 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\uXHJKUUN3ME22MlM4Pzd|IN88US=> NF7B[VZUSU6JRWK=
NALM-6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTZwNkizPFch|ryP NVvudHZCW0GQR1XS
EB-3 M1zqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLz[ll4UUN3ME23MlA4OjN|IN88US=> NHHNXFFUSU6JRWK=
697 M3\CcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fvUmlEPTB;OT6yOFMzQSEQvF2= MnHzV2FPT0WU
Ramos-2G6-4C10 NXr5UFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTlwNUm4OFIh|ryP NXHEb4V3W0GQR1XS
KNS-81-FD M4S0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDUdZV[UUN3ME25MlY6PjV|IN88US=> NH;qTpdUSU6JRWK=
HUTU-80 NIi3OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTRbJk5UUN3ME25Mlc1PjR{IN88US=> NEn4c49USU6JRWK=
LS-411N NEHSbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj4TWM2OD1zMD6wOVY4KM7:TR?= MUjTRW5ITVJ?
RPMI-8402 M{\2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvKRpdKSzVyPUGwMlEyPiEQvF2= MUHTRW5ITVJ?
KU812 M3rRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWVmlEPTB;MUCuNlk6OSEQvF2= MX7TRW5ITVJ?
EW-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n1c2lEPTB;MUCuOFQzPSEQvF2= MYLTRW5ITVJ?
HC-1 M37lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFyLkS4OFQh|ryP M{X6XHNCVkeHUh?=
NB69 NFnCO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET6eWpKSzVyPUGwMlUxPDNizszN NWW5cYlxW0GQR1XS
MFH-ino MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIixTnRKSzVyPUGwMlg{ODNizszN NHX4XJlUSU6JRWK=
CCRF-CEM M1SyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrhZ5ZKSzVyPUGxMlU6PyEQvF2= NFfzdldUSU6JRWK=
SK-N-DZ M3r1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF{LkC0N|Yh|ryP NF3sXFVUSU6JRWK=
NCI-H720 NVTFc5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHwdXpKSzVyPUGyMlE4ODVizszN NEnvNFFUSU6JRWK=
HCC1187 M2rJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF{LkKwOFEh|ryP MYLTRW5ITVJ?
IST-SL2 NES1SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ja[2lEPTB;MUKuOFg4OiEQvF2= Ml\lV2FPT0WU
KE-37 NETUd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\jTWM2OD1zMj63PVY3KM7:TR?= MUHTRW5ITVJ?
HCC1599 NYTUOGlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7SRYhKSzVyPUGyMlkxPjlizszN NFLKcopUSU6JRWK=
A4-Fuk NXnXeXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T3UmlEPTB;MUKuPVU5PiEQvF2= NVLCUmV7W0GQR1XS
NKM-1 NWTTbldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF|LkK5NlUh|ryP M4jrbnNCVkeHUh?=
BE-13 M3PUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rrW2lEPTB;MUOuO|k5QSEQvF2= MmDXV2FPT0WU
MV-4-11 M2LDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\mW2lEPTB;MUSuNFMzPCEQvF2= MoLNV2FPT0WU
OPM-2 M2q4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XVUWlEPTB;MUSuOFA5PSEQvF2= MlPnV2FPT0WU
KARPAS-422 NUW4UHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLJPZVKSzVyPUG0MlUyOjZizszN NFfFWHpUSU6JRWK=
RPMI-8226 M{PwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLWU5ZjUUN3ME2xOE45QTF3IN88US=> MVzTRW5ITVJ?
KARPAS-45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF3Lke3NVYh|ryP Mke2V2FPT0WU
SK-PN-DW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDzfFBKSzVyPUG1Mlg3OzFizszN MXzTRW5ITVJ?
LC-2 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHzU3VnUUN3ME2xOk4yPTB4IN88US=> NWnYfHFOW0GQR1XS
NCI-H1648 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XiV2lEPTB;MU[uNlU1KM7:TR?= M3Pnc3NCVkeHUh?=
RL95-2 M4DmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrxVVFKSzVyPUG2MlM6PzhizszN Mnn3V2FPT0WU
KNS-42 NX\v[4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF4LkeyO|Qh|ryP MnzFV2FPT0WU
RPMI-6666 NX:0Tml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnuV|lKSzVyPUG2MlkzOTFizszN MonvV2FPT0WU
SIG-M5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjEOHU1UUN3ME2xO{4yQTB|IN88US=> NGPC[WpUSU6JRWK=
VA-ES-BJ NFzrWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjNc|NHUUN3ME2xO{44PDVzIN88US=> MkS4V2FPT0WU
MONO-MAC-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33LXWlEPTB;MUeuPVMyOiEQvF2= NIPn[YtUSU6JRWK=
LAN-6 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDVTWM2OD1zOD63OVU4KM7:TR?= NXnRfFBDW0GQR1XS
A388 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH6dG04UUN3ME2xPU4{ODV7IN88US=> MU\TRW5ITVJ?
SK-NEP-1 NX7xOVdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3lTWM2OD1{MD6yNVMzKM7:TR?= MlPDV2FPT0WU
TE-10 M3jHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K1TWlEPTB;MkCuOVIzOSEQvF2= NYXHWG1EW0GQR1XS
HL-60 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofDTWM2OD1{MD65NFk6KM7:TR?= M{PPWHNCVkeHUh?=
MC116 NYL6RVJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD1{MT63NlIyKM7:TR?= NYjC[mRMW0GQR1XS
SW962 NFfVUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJzLke5NVUh|ryP Mn3UV2FPT0WU
NOMO-1 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXCNlVqUUN3ME2yNk43PTZ2IN88US=> M1ro[3NCVkeHUh?=
CTB-1 M2m3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ{Lki2O|Eh|ryP MVvTRW5ITVJ?
MRK-nu-1 NHO4V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;pcJoxUUN3ME2yNk46ODd2IN88US=> MYPTRW5ITVJ?
GR-ST NYPTdo9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ|Lke2JO69VQ>? Ml\MV2FPT0WU
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ2LkCwN{DPxE1? NXPNZ|lbW0GQR1XS
NCI-H1963 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD1{ND6wO|gzKM7:TR?= M2PjUHNCVkeHUh?=
QIMR-WIL MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4noOWlEPTB;MkSuPFc4OiEQvF2= NUTiNIRIW0GQR1XS
CGTH-W-1 M{ewTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ3LkC3NlMh|ryP M3qy[nNCVkeHUh?=
LP-1 M2e5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QNWJbUUN3ME2yOU43PTVzIN88US=> MV7TRW5ITVJ?
NCI-H748 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4LkWxN|ch|ryP NVP2Z3NtW0GQR1XS
PF-382 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nl[mlEPTB;MkeuNlIzOyEQvF2= NXOzdoZQW0GQR1XS
ATN-1 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XyU2lEPTB;MkeuN|c{OiEQvF2= MXvTRW5ITVJ?
L-540 NITTeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfiW3NKSzVyPUK3MlY1PTlizszN MYnTRW5ITVJ?
LXF-289 NGXWN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD6TWM2OD1{Nz63OVE6KM7:TR?= M4TCdnNCVkeHUh?=
LS-513 NYPzR5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ6LkG4NFch|ryP NGq5ToJUSU6JRWK=
NCI-H1581 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHYNpRKSzVyPUOwMlM6PzZizszN MkTMV2FPT0WU
ES6 M4HjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nGOmlEPTB;M{CuOlg6QSEQvF2= NFPxT3BUSU6JRWK=
SW982 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO2[lNKSzVyPUOwMlg2PjZizszN NHuzSndUSU6JRWK=
DOHH-2 NYXpXYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3MT29XUUN3ME2zNU42QDl|IN88US=> MYnTRW5ITVJ?
DB NYfTbGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN|Lkm0N|Eh|ryP NIrnPWtUSU6JRWK=
MPP-89 NFHzfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HkcGlEPTB;M{SuNVc2PiEQvF2= MlfiV2FPT0WU
LB831-BLC NG\MRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPTU|Y2UUN3ME2zOE42OTh2IN88US=> NXT1SWU{W0GQR1XS
NB5 M{m1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjCOJpPUUN3ME2zOE45PTN3IN88US=> NXf5OplUW0GQR1XS
GB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjs[4tQUUN3ME2zOU4xPDZ7IN88US=> MoDFV2FPT0WU
TE-15 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvQbGdrUUN3ME2zOU4zOjN6IN88US=> MXzTRW5ITVJ?
LC4-1 NILRZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN3LkO4OFch|ryP NXrYUJpWW0GQR1XS
NCI-H747 NYn4Z2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmzPYlkUUN3ME2zOk4yOzZ7IN88US=> M3TNSXNCVkeHUh?=
NTERA-S-cl-D1 NWPWN2UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXydHdKSzVyPUO4Mlc{PDdizszN Mm\DV2FPT0WU
SK-MM-2 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfzZmk3UUN3ME20NE4yOTR4IN88US=> Ml70V2FPT0WU
TGW NUjZUWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD3TWM2OD12MT6wOVY{KM7:TR?= MUnTRW5ITVJ?
ONS-76 NEjVUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HIfmlEPTB;NEKuOFg5OyEQvF2= NGm1bYRUSU6JRWK=
CPC-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD12Mj65PVcyKM7:TR?= MYTTRW5ITVJ?
ES4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S5cmlEPTB;NESuOFE2OyEQvF2= NXTVPYd[W0GQR1XS
Daudi M3TycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuyZYdKSzVyPUS1MlA5OjdizszN M3XYdXNCVkeHUh?=
MOLT-4 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;mbXBpUUN3ME20OU4xQDV|IN88US=> MlflV2FPT0WU
HT-144 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELkfZRKSzVyPUS2MlczPiEQvF2= NH3TN45USU6JRWK=
SW872 M2TzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\yTWM2OD12OD6xPVM{KM7:TR?= MUDTRW5ITVJ?
D-283MED NFf1coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTR6LkO1OFIh|ryP NHjJN49USU6JRWK=
NCI-H2126 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfiUnpKSzVyPUS4Mlg1PzZizszN NF3ufWtUSU6JRWK=
NCI-SNU-16 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaSm17UUN3ME20PU4zOTR|IN88US=> M2S5UXNCVkeHUh?=
CESS NWrQd2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr1TWM2OD12OT61NFg5KM7:TR?= MWjTRW5ITVJ?
A101D M2XFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHUTWM2OD12OT65O|M3KM7:TR?= MlvDV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID